Gepotidacin Novel Oral Antibiotic UTI Gonorrhea — PatSnap Eureka
Gepotidacin: GSK's Phase III Breakthrough for UTI and Gonorrhea
Gepotidacin is a first-in-class oral antibiotic targeting resistant uropathogens and Neisseria gonorrhoeae through a novel topoisomerase inhibition mechanism — offering a critical new option as antimicrobial resistance erodes standard-of-care therapies.
A First-in-Class Topoisomerase Inhibitor with a Distinct Binding Site
Gepotidacin is a first-in-class triazaacenaphthylene antibiotic developed by GSK, analysed extensively through PatSnap's IP analytics platform. It works by inhibiting bacterial type II topoisomerases — specifically DNA gyrase and topoisomerase IV — through a novel binding mechanism that is structurally and functionally distinct from fluoroquinolones.
This distinction is clinically critical: existing fluoroquinolone resistance mutations do not confer cross-resistance to gepotidacin, meaning it retains activity against many strains that have rendered fluoroquinolones ineffective. As fluoroquinolone resistance in E. coli exceeds 20% in many regions, gepotidacin addresses a growing unmet need in the management of uncomplicated urinary tract infections (uUTI).
The World Health Organization has classified Neisseria gonorrhoeae as a high-priority pathogen due to rising resistance to cephalosporins and azithromycin — the current standard-of-care agents — leaving very limited oral treatment options for gonorrhea. Gepotidacin's novel mechanism positions it as a potential single-dose oral alternative for urogenital gonorrhea, including drug-resistant strains.
Understanding the full patent landscape around gepotidacin and competing topoisomerase inhibitors requires deep innovation intelligence. PatSnap's life sciences intelligence tools enable R&D and IP teams to map filing velocity, freedom-to-operate, and competitive positioning across this rapidly evolving space.
Phase III Trial Results: EAGLE-1, EAGLE-2, and EAGLE-3
GSK's gepotidacin Phase III programme spans two distinct indications with pivotal trial data demonstrating efficacy against resistant pathogens.
High Cure Rates Against Drug-Resistant N. gonorrhoeae
The EAGLE-1 Phase III trial evaluated gepotidacin for uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae. Gepotidacin achieved high cure rates, including against isolates resistant to ceftriaxone and azithromycin — the current standard-of-care combination. This positions gepotidacin as a potential single-dose oral alternative for gonorrhea, a critical advance given the WHO's high-priority classification of drug-resistant N. gonorrhoeae.
Single-dose oral potentialNon-Inferiority to Nitrofurantoin in Uncomplicated UTI
The EAGLE-2 and EAGLE-3 Phase III studies evaluated gepotidacin for uncomplicated urinary tract infections. Both trials demonstrated non-inferiority to nitrofurantoin — a widely used first-line agent — establishing gepotidacin's clinical equivalence while offering activity against nitrofurantoin-resistant and fluoroquinolone-resistant uropathogens including E. coli. This dual coverage addresses the growing resistance burden in uUTI management.
Non-inferior to nitrofurantoinRetains Activity Where Fluoroquinolones Fail
Gepotidacin's distinct binding site on bacterial topoisomerases means that strains harbouring common fluoroquinolone resistance mutations remain susceptible. In regions where fluoroquinolone resistance in E. coli exceeds 20%, this represents a substantial clinical advantage. For gonorrhea, activity against ceftriaxone- and azithromycin-resistant isolates addresses the most urgent treatment gaps identified by the CDC and WHO surveillance programmes.
Active vs FQ-resistant strainsNDA Filed: Gepotidacin on Track for FDA Review
Following positive Phase III data from the EAGLE programme, GSK has progressed gepotidacin through regulatory filing. The New Drug Application (NDA) submission to the FDA represents a major milestone for the first novel oral antibiotic class to reach this stage for both uUTI and gonorrhea in over a decade. PatSnap customers in the pharmaceutical sector use Eureka to track regulatory milestones and patent expiry timelines for pipeline assets like gepotidacin.
NDA submitted to FDANovel Oral Antibiotic Pipeline: Development Stage and Resistance Coverage
Patent and clinical literature analysis via PatSnap Eureka reveals the competitive landscape for novel oral antibiotics targeting UTI and gonorrhea.
Novel Oral Antibiotic Pipeline by Development Stage
Gepotidacin (NDA filed) leads the pipeline alongside zoliflodacin (Phase III) and sulopenem etzadroxil (submitted), with pivmecillinam approved in select regions.
Antibiotic Resistance Prevalence by Drug Class and Pathogen
Fluoroquinolone resistance exceeds 20% in E. coli UTI isolates in many regions; N. gonorrhoeae shows high/rising resistance to azithromycin and emerging resistance to cephalosporins.
Novel Oral Antibiotic Pipeline: UTI and Gonorrhea Agents Compared
| Agent | Mechanism Class | Target Indication | Development Stage | Key Differentiator |
|---|---|---|---|---|
| Gepotidacin (GSK) | Triazaacenaphthylene / Topo II inhibitor | uUTI, Gonorrhea | NDA Filed | Novel binding site; active vs FQ-resistant strains; oral single-dose potential for GC |
| Zoliflodacin | Spiropyrimidinetrione / Topo II inhibitor | Gonorrhea | Phase III | Distinct from fluoroquinolones; active vs ceftriaxone-resistant GC; oral |
| Sulopenem etzadroxil / probenecid | Oral penem / beta-lactam | uUTI | Submitted | Oral penem; active vs ESBL-producing E. coli; probenecid boosts urinary levels |
| Pivmecillinam | Penicillin / PBP2 inhibitor | uUTI | Approved (select) | Approved in Europe/Canada; limited US availability; narrow-spectrum oral agent |
| Cefpodoxime proxetil | Oral cephalosporin (repurposing) | Gonorrhea | Phase II / Repurposing | Existing approved agent being studied for GC; lower bar for development |
Map the Full AMR Antibiotic Patent Landscape
PatSnap Eureka searches 2B+ innovation data points to surface competitor patents, clinical trial overlaps, and regulatory signals.
Why Antimicrobial Resistance Makes Gepotidacin Strategically Critical
The global AMR crisis is creating urgent demand for novel oral antibiotics with activity against resistant uropathogens and gonorrhea strains.
Fluoroquinolone Resistance in E. coli Exceeds 20%
In many regions, more than 1 in 5 E. coli isolates causing UTI are resistant to fluoroquinolones — once the first-line oral option. This resistance burden has driven prescribers toward nitrofurantoin and fosfomycin, but gepotidacin offers a structurally novel alternative active against these resistant strains.
WHO High-Priority: Drug-Resistant N. gonorrhoeae
The WHO has designated drug-resistant Neisseria gonorrhoeae a high-priority pathogen. Rising resistance to azithromycin and emerging resistance to cephalosporins — the current dual-therapy standard — leaves virtually no oral treatment options. Gepotidacin's activity against ceftriaxone- and azithromycin-resistant isolates directly addresses this gap.
Oral Formulation Is a Key Strategic Advantage
Many last-resort antibiotics for resistant gonorrhea and complicated UTI require intravenous administration, limiting their use to hospital settings. Gepotidacin's oral bioavailability enables outpatient treatment — a critical factor for uptake, patient adherence, and public health impact in both uUTI and gonorrhea management.
Patent Strategy: Protecting a Novel Mechanism
First-in-class mechanisms generate layered patent estates covering the core compound, synthesis routes, formulations, and method-of-use claims. PatSnap's IP analytics enables teams to map gepotidacin's patent family, identify white spaces for biosimilar or next-generation analogue development, and monitor competitor filings in the topoisomerase inhibitor space.
Gepotidacin and Novel Oral Antibiotics — Key Questions Answered
Gepotidacin is a first-in-class triazaacenaphthylene antibiotic developed by GSK. It works by inhibiting bacterial type II topoisomerases — specifically DNA gyrase and topoisomerase IV — through a novel binding mechanism distinct from fluoroquinolones, which means it retains activity against many fluoroquinolone-resistant strains.
Gepotidacin is being developed as an oral treatment for uncomplicated urinary tract infections (uUTI) caused by common uropathogens including E. coli, and for uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae, including drug-resistant strains.
In Phase III trials for uUTI (EAGLE-2 and EAGLE-3 studies), gepotidacin demonstrated non-inferiority to nitrofurantoin. In the EAGLE-1 gonorrhea trial, gepotidacin achieved high cure rates against Neisseria gonorrhoeae, including isolates resistant to ceftriaxone and azithromycin, positioning it as a potential single-dose oral alternative.
Antimicrobial resistance (AMR) is eroding the efficacy of standard-of-care antibiotics. For UTIs, fluoroquinolone resistance in E. coli exceeds 20% in many regions. For gonorrhea, the WHO has classified Neisseria gonorrhoeae as a high-priority pathogen due to rising resistance to cephalosporins and azithromycin, leaving very limited oral treatment options.
Beyond gepotidacin, the pipeline includes zoliflodacin (a spiropyrimidinetrione topoisomerase inhibitor in Phase III for gonorrhea), sulopenem etzadroxil/probenecid (an oral penem for uUTI), and pivmecillinam, which is approved in some regions. These agents represent diverse mechanisms targeting resistant uropathogens and sexually transmitted infections.
Gepotidacin binds to a unique site on bacterial topoisomerases that differs from the fluoroquinolone binding site. This distinct mechanism of action means existing fluoroquinolone resistance mutations do not confer cross-resistance to gepotidacin, making it effective against many currently resistant bacterial strains.
Still have questions? Let PatSnap Eureka answer them with real patent and clinical data.
Ask PatSnap Eureka About GepotidacinAccelerate Your Antibiotic R&D and IP Strategy with AI-Powered Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map novel antibiotic pipelines, track AMR patent landscapes, and identify white-space opportunities in UTI and gonorrhea drug development.
References
- World Health Organization — WHO Priority Pathogens List for R&D of New Antibiotics
- US Centers for Disease Control and Prevention (CDC) — Antibiotic-Resistant Gonorrhea
- European Medicines Agency (EMA) — Antimicrobial Resistance Overview
- ClinicalTrials.gov — EAGLE-1: Gepotidacin vs Ceftriaxone for Gonorrhea (Phase III)
- ClinicalTrials.gov — EAGLE-2: Gepotidacin vs Nitrofurantoin for uUTI (Phase III)
- PatSnap — Life Sciences Innovation Intelligence Platform
- PatSnap — IP Analytics and Patent Landscape Analysis
- PatSnap — Customer Success in Pharmaceutical R&D
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Patent and clinical literature analysis performed via PatSnap Eureka.
PatSnap Eureka searches patents and research to answer instantly.